Viewing Study NCT07463768

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:16 PM
Ignite Modification Date: 2026-03-30 @ 2:25 AM
Study NCT ID: NCT07463768
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-11
First Post: 2026-02-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
Sponsor: French Innovative Leukemia Organisation
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None acute myeloid leukemia and IDH1 mutation View
None complete remission after intensive chemotherapy View
None ivosidenib and oral azacitidine View